|Articles|April 1, 2015

BioPharm International

  • BioPharm International-04-01-2015
  • Volume 28
  • Issue 4

IV Bag Filling and Closing System Eliminates Contamination

Bausch’s second generation Type 529 is a semi-automatic IV bag filling and closing machine designed for aseptic packaging of infusions, parenteral drugs, and other fluids with a fully integrated automatic closing system to eliminate possible contamination.

 

Bausch’s second generation Type 529 is a semi-automatic IV bag filling and closing machine designed for aseptic packaging of infusions, parenteral drugs, and other fluids with a fully integrated automatic closing system to eliminate possible contamination. The system handles IV bags from 10 mL-10 L, with the ability to produce up to 1600 aseptic bags in one hour, and the updated design is suited for isolator or closed restricted access barrier systems applications because it eliminates obstruction of the laminar air flow into the open bag.

Up to four filling and closing stations can be added to the system using the original electronics, industrial personal computer, and human machine interface to expand versatility and allow for production growth. Dosing technology options for the system include mass flow, peristaltic pump, servo-operated pinched valve, and rotary piston pumps, all with the option of process control technology. Other options include hard port or flexible tubing closures; high frequency, ultrasonic, or heat sealing technologies; and air evacuating and pre- and/or post-gassing system and can be integrated with clean-in-place or sterilize-in-place systems.

Bausch Advanced Technology Group
 


Related to this article

The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.